Switch theme
Sign up to access all valuation multiples
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
2000
1.5K+
LTM Revenue $608M
LTM EBITDA -$4.9M
$1.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
NovoCure has a last 12-month revenue of $608M and a last 12-month EBITDA of -$4.9M.
In the most recent fiscal year, NovoCure achieved revenue of $605M and an EBITDA of -$110M.
NovoCure expects next 12-month revenue of XXX and NTM EBITDA of XXX
See NovoCure valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $509M | $605M | XXX | XXX | XXX |
| Gross Profit | $423M | $381M | XXX | XXX | XXX |
| Gross Margin | 83% | 63% | XXX | XXX | XXX |
| EBITDA | -$177M | -$110M | XXX | XXX | XXX |
| EBITDA Margin | -35% | -18% | XXX | XXX | XXX |
| Net Profit | -$92.5M | -$207M | XXX | XXX | XXX |
| Net Margin | -18% | -34% | XXX | XXX | XXX |
| Net Debt | $450M | $328M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, NovoCure's stock price is $17.
NovoCure has current market cap of $1.8B, and EV of $1.5B.
See NovoCure trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.5B | $1.8B | XXX | XXX | XXX | XXX | $-1.68 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, NovoCure has market cap of $1.8B and EV of $1.5B.
NovoCure's trades at 2.5x LTM EV/Revenue multiple, and -312.0x LTM EBITDA.
Analysts estimate NovoCure's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for NovoCure and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.5B | XXX | XXX | XXX |
| EV/Revenue | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | -14.1x | XXX | XXX | XXX |
| P/E | -10.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -22.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpNovoCure's NTM/LTM revenue growth is 4%
NovoCure's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, NovoCure's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate NovoCure's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for NovoCure and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -18% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -38% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -14% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 40% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 31% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 35% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 106% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NovoCure acquired XXX companies to date.
Last acquisition by NovoCure was XXXXXXXX, XXXXX XXXXX XXXXXX . NovoCure acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was NovoCure founded? | NovoCure was founded in 2000. |
| Where is NovoCure headquartered? | NovoCure is headquartered in United States of America. |
| How many employees does NovoCure have? | As of today, NovoCure has 1.5K+ employees. |
| Who is the CEO of NovoCure? | NovoCure's CEO is Ms. Ashley Cordova. |
| Is NovoCure publicy listed? | Yes, NovoCure is a public company listed on NAS. |
| What is the stock symbol of NovoCure? | NovoCure trades under NVCR ticker. |
| When did NovoCure go public? | NovoCure went public in 2015. |
| Who are competitors of NovoCure? | Similar companies to NovoCure include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of NovoCure? | NovoCure's current market cap is $1.8B |
| What is the current revenue of NovoCure? | NovoCure's last 12-month revenue is $608M. |
| What is the current EBITDA of NovoCure? | NovoCure's last 12-month EBITDA is -$4.9M. |
| What is the current EV/Revenue multiple of NovoCure? | Current revenue multiple of NovoCure is 2.5x. |
| What is the current EV/EBITDA multiple of NovoCure? | Current EBITDA multiple of NovoCure is -312.0x. |
| What is the current revenue growth of NovoCure? | NovoCure revenue growth between 2023 and 2024 was 19%. |
| Is NovoCure profitable? | Yes, NovoCure is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
